利拉鲁肽治疗口服降糖药疗效欠佳2型糖尿病再添新证

在这项随机临床试验中，研究者对甘精胰岛素与利拉鲁肽的安全性和有效性进行比较。研究发现，两组试验组中患者糖化血红蛋白（HbA1c）水平达到率相似（HbA1c＜7%），分别为48.4%和45.9%。进一步分析发现，甘精胰岛素治疗组症状性低血糖发生率增加。利拉鲁肽治疗组胃肠道不良事件发生率增加，且有更多的患者因无法耐受这些不良事件而退出研究。

该研究提示，对于口服药物治疗、但血糖控制欠佳的2型糖尿病患者而言，加用甘精胰岛素和利拉鲁肽都能显著改善HbA1c水平。

独家授权，未经许可，请勿转载

In this randomized study comparing the safety and effectiveness of insulin glargine with liraglutide, glycated hemoglobin (HbA1c) levels <7% were attained in a similar proportion of patients in both groups (48.4% vs 45.9%). The glargine group had a greater incidence of symptomatic hypoglycemia. The liraglutide group had a greater incidence of gastrointestinal adverse events as well as a greater number of participants withdrawing due to adverse events.

Insulin glargine and liraglutide can both improve HbA1c levels in people with type 2 diabetes poorly controlled with oral agents.

Diabetes, Obesity & Metabolism

Comparison of Insulin Glargine and Liraglutide Added to Oral Agents in Patients With Poorly Controlled Type 2 Diabetes

Diabetes Obes Metab 2015 Feb 01;17(2)170-178, D D'Alessio, HU Häring, B Charbonnel, P de Pablos-Velasco, C Candelas, MP Dain, M Vincent, V Pilorget, H Yki-Järvinen

---------------------------------------------------------------------------------------------------------------------------------------------
欢迎关注爱唯医学网糖尿病及内分泌官方微信